157 related articles for article (PubMed ID: 34684610)
1. Serum Osteoprotegerin Is an Independent Marker of Metabolic Complications in Non-DialysisDependent Chronic Kidney Disease Patients.
Rymarz A; Romejko K; Matyjek A; Bartoszewicz Z; Niemczyk S
Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684610
[TBL] [Abstract][Full Text] [Related]
2. Serum Osteoprotegerin Is an Independent Marker of Left Ventricular Hypertrophy, Systolic and Diastolic Dysfunction of the Left Ventricle and the Presence of Pericardial Fluid in Chronic Kidney Disease Patients.
Romejko K; Rymarz A; Szamotulska K; Bartoszewicz Z; Niemczyk S
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889849
[TBL] [Abstract][Full Text] [Related]
3. Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease Patients Not Treated with Dialysis.
Romejko K; Rymarz A; Szamotulska K; Bartoszewicz Z; Rozmyslowicz T; Niemczyk S
Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364925
[TBL] [Abstract][Full Text] [Related]
4. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5.
Marques GL; Hayashi S; Bjällmark A; Larsson M; Riella M; Olandoski M; Lindholm B; Nascimento MM
Sci Rep; 2021 Jan; 11(1):2473. PubMed ID: 33510348
[TBL] [Abstract][Full Text] [Related]
7. The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study.
Chae SY; Chung W; Kim YH; Oh YK; Lee J; Choi KH; Ahn C; Kim YS
J Korean Med Sci; 2018 Dec; 33(53):e322. PubMed ID: 30595681
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.
Guven S; Gokce I; Cicek N; Yaman A; Vatansever P; Alpay H
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1383-1390. PubMed ID: 33068383
[TBL] [Abstract][Full Text] [Related]
9. Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.
Demir P; Erdenen F; Aral H; Emre T; Kose S; Altunoglu E; Dolgun A; Inal BB; Turkmen A
J Clin Lab Anal; 2016 Nov; 30(6):811-817. PubMed ID: 26991325
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events.
Yilmaz MI; Siriopol D; Saglam M; Unal HU; Karaman M; Gezer M; Kilinc A; Eyileten T; Guler AK; Aydin İ; Vural A; Oguz Y; Covic A; Ortiz A; Kanbay M
Calcif Tissue Int; 2016 Aug; 99(2):121-30. PubMed ID: 27016924
[TBL] [Abstract][Full Text] [Related]
11. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients.
Bernardi S; Toffoli B; Bossi F; Candido R; Stenner E; Carretta R; Barbone F; Fabris B
BMC Nephrol; 2017 Jul; 18(1):219. PubMed ID: 28683789
[TBL] [Abstract][Full Text] [Related]
12. The relationship between calcification inhibitor levels in chronic kidney disease and the development of atherosclerosis.
Sevinc C; Yilmaz G; Ustundag S
Ren Fail; 2021 Dec; 43(1):1349-1358. PubMed ID: 34583616
[TBL] [Abstract][Full Text] [Related]
13. Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women.
Lewis JR; Lim WH; Ueland T; Wong G; Zhu K; Lim EM; Bollerslev J; Prince RL
PLoS One; 2015; 10(7):e0134266. PubMed ID: 26222774
[TBL] [Abstract][Full Text] [Related]
14. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.
Lee JE; Kim HJ; Moon SJ; Nam JS; Kim JK; Kim SK; Yun GY; Ha SK; Park HC
Korean J Intern Med; 2013 Nov; 28(6):668-77. PubMed ID: 24307842
[TBL] [Abstract][Full Text] [Related]
15. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
[TBL] [Abstract][Full Text] [Related]
16. Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting.
Yuan J; Watanabe M; Suliman M; Qureshi AR; Axelsson J; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2015 Feb; 30(2):274-82. PubMed ID: 23975839
[TBL] [Abstract][Full Text] [Related]
17. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients.
Nakashima A; Carrero JJ; Qureshi AR; Hirai T; Takasugi N; Ueno T; Taniguchi Y; Lindholm B; Yorioka N
Osteoporos Int; 2011 Jun; 22(6):1695-701. PubMed ID: 20812007
[TBL] [Abstract][Full Text] [Related]
18. Renal anemia and hydration status in non-dialysis chronic kidney disease: Is there a link?
Hildegard Stancu S; Stanciu A; Lipan M; Capusa C
J Med Life; 2018; 11(4):293-298. PubMed ID: 30894885
[No Abstract] [Full Text] [Related]
19. Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid-femoral pulse wave velocity in hemodialysis patients: a cross sectional study.
Hou JS; Lin YL; Wang CH; Lai YH; Kuo CH; Subeq YM; Hsu BG
BMC Nephrol; 2019 May; 20(1):184. PubMed ID: 31122190
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis.
Janda K; Krzanowski M; Chowaniec E; Kuśnierz-Cabala B; Dumnicka P; Kraśniak A; Podolec P; Sułowicz W
Pol Arch Med Wewn; 2013; 123(4):149-55. PubMed ID: 23535831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
